Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The company patent portfolio for Juno Therapeutics GmbH is focused on Biotechnology & Pharmaceuticals. Currently, the portfolio includes 1 pending office action. This 1 pending office action is being handled within 1 distinct art unit, reflecting a narrow technical scope for the company's current filings. Such a structure often points to a highly targeted intellectual property strategy.
A specific official, 1 distinct examiner, is responsible for the current workload. ZHU, JIANJIAN is the busiest examiner identified in the data, managing 1 busiest examiner pending office action. This concentration of the busiest examiner pending office action under 1 distinct examiner means that the prosecution strategy must be tailored to the specific individual's tendencies. The data shows that 1 distinct art unit is the venue for the company's current patent office interactions. Practitioners should prepare for an examination process that is entirely dependent on the findings of the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011780 | ENGINEERED T CELLS CONDITIONALLY EXPRESSING A RECOMBINANT RECEPTOR, RELATED POLYNUCLEOTIDES AND METHODS | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18011780 | ENGINEERED T CELLS CONDITIONALLY EXPRESSING A RECOMBINANT RECEPTOR, RELATED POLYNUCLEOTIDES AND METHODS | ZHU, JIANJIAN | 1631 | §103 | Final Rejection | — | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial